BioSpace News Archive

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 39,300 shares of Astria’s common stock on April 3, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2023 after the market close on Wednesday, April 26, 2023.

IVERIC bio, Inc. reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 11,800 shares of the Company’s common stock, effective as of April 3, 2023.

Johnson & Johnson announced that its subsidiary LTL Management LLC has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America.

Novotech, the leading Asia Pacific centred biotech CRO has commissioned GlobalData to report on the evolving FDA approval processes for biotechs in Asia Pacific, Europe, and US, including typical impediments to success.

Dr. Hamid Abbasi, a renowned spine surgeon and innovator, has successfully performed the first Inspired Spine Trans-Kambin Oblique Lateral Lumbar Interbody Fusion with Arrow Cage in South America.

Gritstone bio, Inc. announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases, taking place April 15-18, 2023 in Copenhagen, Denmark.

Protagonist Therapeutics announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share.

Americans diagnosed with hypothyroidism now have access to greater dosage flexibility for levothyroxine therapy. IBSA Pharma Inc. is introducing three new dosage strengths of Tirosint® (levothyroxine sodium) capsules to treat hypothyroidism.